Page 5 - அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA approves immunotherapy for first-line treatment of advanced gastric cancer Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. Today s approval is the first treatment in more than a decade to show a survival benefit for patients with advanced or metastatic gastric cancer who are being treated for the first time. The FDA is committed to bringing new safe and effective treatment options like Opdivo to patients with advanced cancer.

Richard pazdurEmily hendersonAustralian therapeutic goods administrationBrazilian health regulatory agencyOncology centerDrug administrationHealth canadaOffice of oncologic diseasesBristol myers squibb companyActing directorOncologic diseasesDrug evaluationPriority reviewOrphan drugBristol myers squibbProject orbis